Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Neuropace, Inc. - Common Stock
(NQ:
NPCE
)
12.50
UNCHANGED
Delayed Quote
Updated: 4:00 PM EST, Nov 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Neuropace, Inc. - Common Stock
< Previous
1
2
3
Next >
NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026
October 29, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
September 01, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
August 31, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
August 11, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
July 28, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting
May 29, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
May 29, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
May 12, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026
April 29, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
April 27, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
April 10, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace to Present at the Leerink Global Healthcare Conference
March 05, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
March 03, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026
February 20, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
January 13, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 31, 2025
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy
December 17, 2025
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
December 08, 2025
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting
December 02, 2025
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services
November 24, 2025
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
November 04, 2025
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025
October 22, 2025
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace to Participate in Upcoming Healthcare Conferences
August 28, 2025
From
NeuroPace, Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
July 06, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
July 01, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
June 30, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
June 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
June 26, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
June 25, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
June 24, 2025
Via
ACCESS Newswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
